Literature DB >> 31204981

Anti-Xa assays: What is their role today in antithrombotic therapy?

Erika Hutt Centeno1,2, Michael Militello3, Marcelo P Gomes4,5.   

Abstract

Although some suggest anti-Xa assays should be the preferred method for monitoring intravenous unfractionated heparin therapy, which method is best is unknown owing to the lack of large randomized controlled trials correlating different assays with clinical outcomes. This article provides an overview of heparin monitoring and the pros, cons, and clinical applications of anti-Xa assays.
Copyright © 2019 Cleveland Clinic.

Entities:  

Year:  2019        PMID: 31204981     DOI: 10.3949/ccjm.86a.18029

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  2 in total

1.  COVID-19 and venous thromboembolism: current insights and prophylactic strategies.

Authors:  Pasquale Ambrosino; Alessandro Di Minno; Mauro Maniscalco; Matteo Nicola Dario Di Minno
Journal:  Ann Med       Date:  2020-07-13       Impact factor: 4.709

2.  Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens.

Authors:  Mohammed A Hamad; Shereen A Dasuqi; Aamer Aleem; Rasha A Omran; Rakan M AlQahtani; Fahad A Alhammad; Abdulaziz H Alzeer
Journal:  SAGE Open Med       Date:  2021-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.